erlotinib hydrochloride has been researched along with Carcinoma, Transitional Cell in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bleilevens, A; Denecke, B; Denzinger, S; Ecke, T; Eltze, E; Eyll, M; Gaisa, NT; Geelvink, M; Gereitzig, M; Grimm, T; Herrmann, E; Horst, D; Knuechel, R; Maurer, A; Maurer, J; Rose, M; Rüchel, N; Toma, M; Vögeli, TA; Waldmann, T; Wenz, M; Wirtz, J | 1 |
| Brenner, PC; Goldstein, D; Hayes, VM; Qu, XJ; Russell, PJ; Yang, JL | 1 |
| Baumgart, ED; Bernier, T; Cohen, MS; Jacobs, MA; Libertino, JA; Neto, BS; Rieger-Christ, KM; Summerhayes, IC; Wotkowicz, C | 1 |
3 other study(ies) available for erlotinib hydrochloride and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Line, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Small Interfering; Signal Transduction; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.
Topics: Analysis of Variance; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Interferon-alpha; Mutation; Protein Kinase Inhibitors; Quinazolines; Urinary Bladder Neoplasms | 2007 |
Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
Topics: Blotting, Western; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; STAT3 Transcription Factor; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 2007 |